New York 2025-2026 Regular Session

New York Assembly Bill A04296

Introduced
2/4/25  
Refer
2/4/25  

Caption

Limits the off label use of antipsychotic drugs with black box warnings on elderly patients with dementia; provides for professional misconduct for any health care professional who uses such drug on such patient.

Summary

This bill would add a new section to the Public Health Law restricting the use of antipsychotic drugs that carry FDA black box warnings when prescribed to elderly patients with dementia. It defines “off label” use, “black box warning,” “chemical restraint,” and the covered antipsychotic drugs, and applies the restriction to patients in residential health care facilities, adult care facilities, hospitals, and other health care settings that care for people with dementia. Under the bill, such drugs could not be used off label or as chemical restraints for a patient known to have dementia. The only exception would be an emergency situation, and then only when ordered by a health care professional who specializes in dementia or is specifically trained in dementia treatment, and only when necessary to protect the life, health, or safety of the patient or another person. The bill also requires immediate documentation in the medical record and prompt notice to the patient’s lawful representative and certain family members.

Impact

The bill would create a new statutory prohibition in the Public Health Law on off-label use of black-box-warning antipsychotics for dementia patients, while preserving existing consent rules and scope-of-practice limits. It would also amend the Education Law to make noncompliance professional misconduct, exposing health care professionals to discipline under the state’s professional misconduct framework. The commissioner would be authorized to adopt implementing regulations, and the act would take effect 30 days after enactment.

Sentiment

The bill’s framing and caption suggest a protective, patient-safety-oriented purpose focused on preventing inappropriate sedation of vulnerable elderly dementia patients. No committee transcript or vote record is available, so there is no direct evidence of support or opposition in the provided materials. Based on the text alone, the measure appears to be motivated by concern over misuse of antipsychotics in long-term care and hospital settings.

Contention

The main point of contention is likely to be the bill’s strict limitation on off-label prescribing and its narrow emergency exception, which could be viewed by some clinicians and facilities as constraining medical judgment in behavioral crises. Another likely issue is the bill’s treatment of violations as professional misconduct, which raises the stakes for physicians and other prescribers. Supporters would likely emphasize protection against chemical restraint and overmedication of dementia patients, while critics may argue the bill could make it harder to manage acute agitation or safety risks in institutional settings.

Companion Bills

NY S04380

Same As Limits the off label use of antipsychotic drugs with black box warnings on elderly patients with dementia; provides for professional misconduct for any health care professional who uses such drug on such patient.

Previously Filed As

NY A03374

Limits the off label use of antipsychotic drugs with black box warnings on elderly patients with dementia; provides for professional misconduct for any health care professional who uses such drug on such patient.

NY S04380

Limits the off label use of antipsychotic drugs with black box warnings on elderly patients with dementia; provides for professional misconduct for any health care professional who uses such drug on such patient.

RI H7278

Permits healthcare professionals to diagnose and treat patients remotely with store-and-forward technology when provision of services in such manner is consistent with the standard of care.

AZ SB1672

AHCCCS; antipsychotic drugs; authorization

TX HB2264

Relating to information provided by friends and family for inclusion into certain patients' medical records and to health care professionals' duties when discharging certain patients from inpatient care.

NY A08081

Strengthens protections for patients regarding sexual misconduct by medical providers; requires medical expert consultants involved in investigations disclose conflicts of interest and to not be under investigation, on warning, or on probation; requires a zero-tolerance policy to be adopted and training to be provided on sexual misconduct by the board for professional misconduct; includes provisions related to the right to have a chaperone; includes sexual misconduct in the definition of professional misconduct.

AZ HB2335

health professionals; patients; vaccination status

TX SB90

Relating to patient access to prescription drugs for off-label use.

MO HB1928

Creates provisions relating to immunity from liability for health care professionals who inquire about potential dangers in patients' homes

NJ S1979

Requires parents and guardians be provided access to medical records of minor patients; provides immunity to health care facilities and professionals that provide access to records.

Similar Bills

RI S0786

Prohibits prior authorization or a step therapy protocol for the prescription of a nonpreferred medication on their drug formulary used to assess or treat an enrollee's bipolar disorder, schizophrenia or schizotypal.

WI SB83

Utilization management controls for antipsychotic prescription drugs under the Medical Assistance program. (FE)

WI AB54

Utilization management controls for antipsychotic prescription drugs under the Medical Assistance program. (FE)

AZ SB1672

AHCCCS; antipsychotic drugs; authorization

MI HR0082

A resolution to declare May 5-9, 2025, as Tardive Dyskinesia Awareness Week in the state of Michigan.

NJ A2120

Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

NJ S3165

Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

DE SCR66

Designating The First Full Week Of May As "tardive Dyskinesia Awareness Week" In Delaware.